Is 10x Genomics (TXG) Fully Valued Following Its Lausanne Cancer Diagnostics Collaboration?
10x Genomics (TXG) stock is in focus after the company announced a multi year research collaboration with Lausanne University Hospital to study cancer diagnostics using its single cell and spatial platforms.
See our latest analysis for 10x Genomics.
The Lausanne collaboration lands at a moment when 10x Genomics has been in sharp focus, with the share price at US$47.27 and a 30 day share price return of 21.05% feeding into a 90 day share price return of 110.74% and a 1 year total shareholder return of 261.39%. However, the 3 year and 5 year total shareholder returns show material declines, which highlights how recent momentum contrasts with a weaker longer term record.
If this oncology partnership has you thinking about where else advanced biology and data driven tools could reshape healthcare, it may be worth scanning a wider field of 41 healthcare AI stocks
After a move like 10x Genomics has just had, some investors lean into momentum, while others prefer to wait for a cooler entry. How does the current valuation compare with that recent surge?
Most Popular Narrative: 135% Overvalued
On the most followed narrative, 10x Genomics has a fair value estimate of $20.14, which sits well below the last close at $47.27.
Global investment in genomics, including collaborations like the TISHUMAP initiative and large-scale AI-driven studies using 10x platforms, is increasing the customer base and creating new high-throughput, high-complexity data requirements, which 10x is well positioned to supply, driving expanded total addressable market and future revenue upside.
Analysts are tying this fair value to specific assumptions on steady revenue growth, margin improvement and a future earnings multiple that leans on industry level pricing power. Curious which mix of growth expectations and profit margins has to hold up for that gap between $20.14 and $47.27 to make sense.
Result: Fair Value of $20.14 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still pressure points that could challenge this 10x Genomics narrative, including softer academic funding and discounted instrument pricing that may weigh on revenue and margins.
Find out about the key risks to this 10x Genomics narrative.
Another View on 10x Genomics Using Cash Flows
The analyst narrative around 10x Genomics leans on earnings and price targets, yet the Simply Wall St DCF model points in a different direction. On that framework, TXG at $47.27 is trading about 44.2% below an estimated fair value of $84.68, which frames the current share price as discounted rather than stretched. Which set of assumptions do you find more convincing?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 10x Genomics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed signals around 10x Genomics leave you unsure, take a close look at the underlying data and form your own view around 2 key rewards and 2 important warning signs
Looking for more stock ideas beyond 10x Genomics?
If 10x Genomics has sharpened your focus on opportunities, do not stop here. The right shortlist can save you time and help you spot ideas others overlook.
- Target potential mispricings by scanning for companies that combine quality fundamentals with appealing valuations using the 55 high quality undervalued stocks.
- Strengthen your watchlist with businesses that have resilient finances and cleaner balance sheets through the solid balance sheet and fundamentals stocks screener (45 results).
- Spot early stage opportunities that still meet higher quality hurdles by checking the 21 elite penny stocks with strong financials before the crowd pays attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com